Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment
In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2025-01-01
|
| Serie: | Journal for ImmunoTherapy of Cancer |
| Accesso online: | https://jitc.bmj.com/content/13/1/e010207.full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
